Abstract

Fresenius Medical Care AG & Co. KGaA will release first-quarter 2026 results Pre-Market on May 5, 2026, with current-quarter forecasts pointing to lower revenue year over year and improving per-share earnings, while investors weigh regulatory headwinds and execution on cost initiatives.

Market Forecast

Consensus for the current quarter points to revenue of 4.53 billion euros, implying a 5.09% year-over-year decline, EBIT of 443.05 million euros, implying a 3.59% year-over-year decline, and adjusted EPS of 0.52, implying a 36.85% year-over-year increase. Forecasts do not specify gross margin or net margin for the quarter, which keeps the focus on operating leverage and cost containment to defend profitability against top-line pressure.

The core care-services franchise remains the primary revenue engine and is expected to hinge on stable treatment volumes, U.S. reimbursement dynamics, and ongoing savings from the multiyear efficiency program. The most promising near-term contribution appears to be from healthcare products, supported by steady equipment and disposables demand; last quarter, this segment generated an estimated 1.14 billion euros based on the reported mix, while group revenue grew 7.10% at constant currency (segment-specific year-over-year growth was not disclosed).

Last Quarter Review

In the prior quarter, Fresenius Medical Care AG & Co. KGaA delivered revenue of 5.07 billion euros (-0.30% year over year), a gross profit margin of 27.39%, GAAP net profit attributable to shareholders of 327.00 million euros with a 6.45% net profit margin, and adjusted EPS of 0.72 (+58.24% year over year). Net profit increased 19.03% quarter over quarter, reflecting improved operating efficiency and favorable items within the period.

A key highlight was operating performance: EBIT of 705.00 million euros grew 44.17% year over year and exceeded the prior estimate by 115.99 million euros, underscoring continued traction from cost control and portfolio execution despite currency headwinds. Within the revenue mix, care services accounted for approximately 66.73% (about 3.38 billion euros), healthcare products 22.49% (about 1.14 billion euros), and insurance contracts 10.78% (about 0.55 billion euros), while total revenue declined 0.30% year over year (up 7.10% at constant currency); U.S. treatment volumes softened slightly late in the quarter.

Current Quarter Outlook

Main Business: Care Services

Care services remain the largest revenue contributor, and the current quarter’s performance should be driven by volume stability, payer mix in the U.S., and the pace of efficiency gains. The guidance tone for the year flagged regulatory headwinds after a period in which profitability benefited from policy-related support and cost measures, making execution discipline critical this quarter. Against a forecast revenue decline of 5.09% year over year at the group level, the services business will likely need to compensate with operating discipline—labor efficiency, scheduling optimization, and reduced overtime usage—to maintain margin quality despite potentially limited pricing tailwinds.

A practical marker for investors is the relationship between treatment volumes and fixed-cost absorption at clinics. Even small changes in same-clinic utilization can translate to disproportionate gross margin moves, given the capital intensity and staffing structure. While the prior quarter’s net margin of 6.45% demonstrated progress, this quarter’s margin trajectory will depend on whether staffing, procurement, and supply usage efficiencies are sustained while treatment volumes hold broadly stable. If volumes are flat to slightly positive, incremental savings should drop through to EBIT, which could offset part of the top-line pressure implied by the revenue forecast.

The U.S. revenue contribution remains central. Changes in Medicare-related reimbursement and the cadence of value-based or integrated arrangements can shift profitability between periods. The company’s cost-savings program is now embedded in operating routines; incremental benefit this quarter will come from tighter clinic-level performance management, smarter scheduling across shifts, and procurement discipline on consumables. On balance, consensus sees a step back in revenue but resilience in EPS; translating that into services means fewer pricing levers and more reliance on cost levers, implying investors will scrutinize wage inflation, overtime hours per treatment, and clinic utilization metrics.

Most Promising Business: Healthcare Products

Healthcare products—comprising machines, disposables, and related equipment—looks poised to hold up relatively well, with last quarter’s mix-based estimate at 1.14 billion euros on a group revenue base of 5.07 billion euros. This quarter, product demand is supported by recurring usage of disposables and replacement cycles for equipment, while procurement and logistics have broadly normalized compared with prior disruptions. The products line typically offers attractive incremental margins when volume is steady, which can help buffer group EBIT if service revenue growth is subdued.

Within products, contract structures and pass-through mechanisms matter for price realization. Where price increases were negotiated in recent cycles, they can still contribute to year-over-year support, even if new placements moderate. Moreover, consistent disposables usage linked to installed equipment can sustain revenue predictability. Given consensus for EBIT of 443.05 million euros (-3.59% year over year), a modest outperformance in products gross margin or mix shift toward higher-margin items could close part of the implied EBIT gap. Conversely, if volume softness emerges in certain geographies, it would be important to see product mix skew toward higher-value categories to defend margins.

From a cash conversion perspective, products can aid working-capital discipline. Predictable inventory turns and improved supplier terms can limit inventory build and support operating cash flow, which investors will parse closely in light of the EPS resilience forecast. This quarter, the key watch items in products are shipment phasing, any residual supply chain cost overhangs, and the sustainability of price-mix benefits. Incremental commentary on order intake quality, backlog, or replacement-cycle visibility would also guide how much margin support products can provide in coming quarters.

What Will Move the Stock This Quarter

The stock’s near-term performance is likely to be driven by whether revenue and EBIT land near the 4.53 billion euros and 443.05 million euros marks, respectively, and whether adjusted EPS meets or beats the 0.52 forecast. A revenue miss without offsetting margin upside could clash with the narrative that cost efficiencies are sufficient to preserve earnings power, while an EPS beat with stable or improving gross margin would validate the current consensus that per-share earnings can rise even as revenue dips. Investors will also monitor the mix between services and products: a larger-than-expected products contribution, coupled with tight operating expense control, would be interpreted favorably for cash generation and EBIT quality.

Policy and reimbursement signals represent another potential swing factor. Commentary on the year’s trajectory in the U.S.—including expectations for the balance of reimbursement updates vs. cost inflation—will be gauged against the earlier communication that regulatory headwinds could cap revenue and earnings growth. Clarity on the net effect of any U.S. adjustments and how they compare with the prior year’s policy-related benefits will shape how sustainable the margin structure appears.

Currency translation remains a material consideration. The prior quarter’s revenue decline of 0.30% year over year contrasted with a 7.10% increase at constant currency, highlighting the potential divergence between reported and underlying trends. If the euro strengthens further against key billing currencies, reported revenue could undershoot underlying growth. Conversely, stable FX would help narrow the gap between constant-currency and reported metrics, simplifying comparisons and potentially reducing volatility in headline results.

Operational metrics will be examined in detail. In care services, watchers will look for signals of treatment-volume trend stabilization, staffing metrics such as hours per treatment, and procurement cost progress on disposables. For products, shipment timing, backlogs, and price-mix commentary will inform gross margin expectations for the remainder of the year. Finally, any update on the pace and scale of the efficiency program—how much in-year benefit is embedded in the EBIT profile—will influence how investors frame the full-year outlook.

Analyst Opinions

The directional ratio of bullish vs. bearish views over the recent period is 0:100, with multiple institutions maintaining Sell or cautious stances while most other published notes stayed Neutral; the majority view we present here is bearish.

Jefferies has reiterated a Sell rating with a price objective near the low-to-mid €30s, reflecting concern that the company’s outlook for 2026 implies a constrained top-line trajectory and pressure on operating momentum as policy tailwinds normalize. Their stance emphasizes that year-ahead revenue guidance is broadly flat when excluding currency, with adjusted operating profit guided to a range approximating mid-single-digit movement in either direction, which in their view signals limited visibility on earnings expansion in the near term. Combined with modest U.S. volume softness in the latest quarter and a heavy reliance on cost levers, Jefferies argues that valuation needs to reflect the risk that EPS resilience proves sensitive to small deviations in volumes or labor and supply costs.

UBS has also maintained a Sell view with a target in the high €30s, focusing on the gap between midterm ambitions and the immediate-year guide. The bank notes that translating broadly flat revenue expectations and a narrow operating profit range into consistent EPS growth requires sustained execution on cost programs and benign exogenous conditions, both of which carry uncertainty. In this framework, UBS sees limited room for error, especially if FX remains a drag on reported revenue, or if U.S. reimbursement and volume trends do not improve sequentially during the year.

Comments from a leading U.S. bulge-bracket firm underscore the same caution: the firm interprets the annual outlook as weaker than anticipated and believes achieving midterm goals now requires a steeper acceleration in growth later in the year. This sequencing raises the bar for quarterly delivery, increasing the sensitivity of the equity story to near-term misses on revenue or margin. In their view, the mix of a 5.09% year-over-year revenue decline expected this quarter and a 3.59% EBIT decline—against a robust 36.85% adjusted EPS growth forecast—introduces a debate about sustainability: if EPS beats rely primarily on cost and below-the-line items while topline and EBIT lag, skepticism could persist.

The bearish camp’s analytical focus for this quarter centers on three tests. The first is whether volumes and reimbursement in the U.S. can stabilize enough to prevent deterioration in clinic-level economics, given that small changes in utilization have magnified effects on margins. The second is the durability of cost savings—especially labor efficiency and procurement benefits—as these are not one-time events but must be maintained or extended to defend the P&L. The third is the alignment between reported and underlying trends: if FX continues to depress reported revenue while constant-currency growth remains positive, the market may still discount reported softness, but consecutive quarters of this divergence can complicate investor perception and compress valuation multiples.

On balance, the bearish majority expects a cautious print and guide combination: revenue likely near 4.53 billion euros with downside bias, EBIT near 443.05 million euros with limited expansion absent stronger volumes, and adjusted EPS around 0.52 benefiting from cost discipline. To shift this narrative, analysts say the company would need to offer clearer evidence that services volumes are turning up in its largest market, that the products franchise is contributing incrementally to gross margin beyond normal seasonality, and that in-year cost savings materially exceed prior run rate. Absent that confirmation, the prevailing view remains that risks around policy, FX, and operational gearing warrant a conservative stance in the near term.